Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659363 | 1.00 | PTGS2 (0.35) | PTGS2CES2CES1ALDH1A1TSHR | |
| SCHEMBL3773771 | 0.87 | ALDH1A1 (0.33) | CES2CES1ALDH1A1TSHRACHE | |
| SCHEMBL3773765 | 0.87 | ALDH1A1 (0.33) | CES2CES1ALDH1A1TSHRACHE | |
| SCHEMBL3661741 | 0.87 | CES2 (0.38) | PTGS2CES2CES1MEN1KMT2A | |
| SCHEMBL3766720 | 0.87 | CES2 (0.38) | PTGS2CES2CES1MEN1KMT2A | |
| SCHEMBL3656662 | 0.84 | TRPA1 (0.38) | PTGS2CES2CES1ALDH1A1MEN1 | |
| SCHEMBL3770487 | 0.84 | TRPA1 (0.38) | PTGS2CES2CES1ALDH1A1MEN1 | |
| SCHEMBL3776448 | 0.82 | MEN1 (0.35) | PTGS2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL3661208 | 0.82 | MEN1 (0.35) | PTGS2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL3663628 | 0.81 | ALDH1A1 (0.33) | ALDH1A1TSHRACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, NOX5, TET1 | PTGS2 376/4885CES2 295/4885CES1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.